News

MADISON, WI - Gentel® Biosciences, a protein microarray life sciences company, announces the launch of the APiX™ Cancer Biomarker Array Kit. This single-capture antibody microarray and protein labeling system is the only commercially available research tool of its kind that is validated to show the detectable and specific capture of target proteins in serum to ensure the most reliable results.

The APiX™ Cancer Biomarker Array Kit measures the relative abundance of forty-seven human cancer-related proteins in eight serum samples simultaneously. The Array Kit also provides a more cost-effective and efficient means to analyze samples than other protein profiling arrays. Research applications include serum and plasma profiling, biomarker discovery and pre-clinical analysis.

MADISON, Wisc. - GenTel BioSciences, Inc., a protein chip-based life sciences company, has appointed Chris Kendrick-Parker as a new member of the company’s Board of Directors.

“Chris will play an important role in helping the Board and executive management guide the future of GenTel. His experience and success in our industry will help us to ensure that we are appropriately envisioning our future and setting the right performance goals,” said Alex D. Vodenlich, President & CEO.

MADISON, WI —GenTel BioSciences, Inc., a protein chip-based life sciences company, has added two internationally renowned scientists to its Scientific Advisory Board (SAB). Dr. Reinhard Hiller and Prof. Jonathan Blackburn, both scientists at the Centre for Proteomic & Genomic Research (CPGR) in Cape Town, South Africa, will join Drs. Brian Haab and Lloyd Smith as scientific advisors.

“The SAB plays an integral role in helping us evaluate new technologies as well trying those technologies once developed in their laboratories. We benefit greatly from their extensive combined knowledge of the protein array market as well as their scientific background,” said Bryce Nelson, Ph.D., Vice President of Research & Development, who facilitates interaction with the Board.

MADISON, WI -- GenTel BioSciences, Inc., a protein chip-based life sciences company, has acquired the protein chip platform assets of GlaxoSmithKline, Inc., one of the world’s largest pharmaceutical companies. GenTel was formed six years ago and this acquisition is a major step forward in their growth and capability to serve the life science industry.

“This acquisition means GenTel has significantly expanded its capabilities and further strengthens our position in offering our customers the best in multiplexed immunoassay products and services,” said GenTel President and CEO Alex D. Vodenlich.

“In one fell swoop, this puts GenTel into the front ranks of service providers to the life science industry,” said Vodenlich. “This accelerates our business tremendously.”

Madison, WI - GenTel BioSciences, Inc., a privately-held protein chip-based life sciences company, recently completed a critical round of financing activity raising over two million dollars, announced its President and Chief Executive Officer Alex Vodenlich.

Two prominent Wisconsin-based investor organizations contributed the majority of the financing; NEW Capital Fund, LP, based in Appleton, Wisconsin and Wisconsin Investment Partners, LLC, a life science-oriented angel investment network based in Madison.

NEW Capital Fund targets companies in Wisconsin with the potential for rapid growth and that are certifiable under Wisconsin’s Act 255 investment tax credit program, according to the Fund’s general partner Charlie Goff. NEW Capital Fund chose to invest in GenTel BioSciences as the company has already proven itself as a sound and promising venture.

MADISON, WI – Dr. Anna Astriab-Fisher, a scientist specializing in immunoassay protocols at GlaxoSmithKline, Inc., has been named Vice President of Assay Development at GenTel Biosciences, Inc., the Madison-based protein chip-based life sciences company, it was announced today.

“Dr. Astriab-Fisher will be leading GenTel’s multiplex immunoassay development efforts," said Alex Vodenlich, GenTel’s President and Chief Executive Officer. “Our recruitment of Dr. Astriab-Fisher is another concrete example of GenTel’s continued strong commitment to the multiplex immunoassay market," he added.

Madison, WI, USA and Grand Rapids, Michigan – GenTel BioSciences, Inc., and The Van Andel Research Institute (VARI) today announced an exclusive agreement granting GenTel the right to commercialize a novel microarray technology for measuring variations in the glycosylation of proteins.

Glycosylation is the chemical addition of a sugar molecule to a protein after its synthesis. Changes in the glycosylation of proteins are associated with many types of cancer.

The technology uses antibody microarrays to profile changes in glycosylation of proteins captured on the surface of a chip. “This technology could lead to the discovery of diseasespecific alterations in protein glycosylation as well as new diagnostic biomarkers,” says Dr. Brian H. Haab of VARI and inventor of the technology.

MADISON, WIS. – GenTel BioSciences, Inc. announced today that it has received a two-year, $1.2 million Phase II SBIR grant from the National Institutes of Health (NIH) to develop a test kit that will be used to aid in the research, rapid diagnosis, and subsequent treatment of respiratory allergies.

“GenTel’s new allergy test will rapidly identify a specific allergic response in a patient using only a few drops of blood,” said Bryce Nelson, Ph.D., GenTel’s Vice President of Research & Development. “Our protein chip uses a new type of test called a multiplex assay to rapidly test a patient’s blood for reactivity to many potential allergens at once.”

MADISON, WIS. – GenTel BioSurfaces, Inc., a privately held life sciences company, announced today that it has changed its name to GenTel BioSciences, Inc.

“We have become more than a surface chemistry company,” says Alex Vodenlich, President and CEO. “The name change reflects our company’s growth into an integrated, full-service multiplex immunoassay company.”

“GenTel’s core business centers on providing cutting-edge biochip products and services to the life science research and drug discovery communities,” explains Vodenlich.

MADISON, WIS. – GenTel BioSurfaces, Inc., a privately held life sciences company, announced today that it has partnered with Taiwan-based Abnova Corporation to combine Abnova’s high throughput protein and antibody content manufacturing capabilities with GenTel’s new custom multiplex immunoassay development service. GenTel’s flagship technology, the PATH™ Protein Microarray System will be used to develop new custom multiplex immunoassays. PATH technology is based on ultra-thin nitrocellulose surface chemistry developed specifically for antibody arrays. The company currently markets and sells PATH products and accessories and will now offer robust multiplex immunoassays using protein content from Abnova.